EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma

Ewing sarcoma is a bone malignancy driven by a translocation event resulting in the fusion protein EWS/FLI1 (EF). EF functions as an aberrant and oncogenic transcription factor that misregulates the expression of thousands of genes. Previous work has focused principally on determining important transcriptional targets of EF, as well as characterizing important regulatory partnerships in EF-dependent transcriptional programs. Less is known, however, about EF-dependent metabolic changes or their role in Ewing sarcoma biology. Therefore, the metabolic effects of silencing EF in Ewing sarcoma cells were determined. Metabolomic analyses revealed distinct separation of metabolic profiles in EF-knockdown versus control-knockdown cells. Mitochondrial stress tests demonstrated that knockdown of EF increased respiratory as well as glycolytic functions. Enzymes and metabolites in several metabolic pathways were altered, including de novo serine synthesis and elements of one-carbon metabolism. Furthermore, phosphoglycerate dehydrogenase (PHGDH) was found to be highly expressed in Ewing sarcoma and correlated with worse patient survival. PHGDH knockdown or pharmacologic inhibition in vitro caused impaired proliferation and cell death. Interestingly, PHGDH modulation also led to elevated histone expression and methylation. These studies demonstrate that the translocation-derived fusion protein EF is a master regulator of metabolic reprogramming in Ewing sarcoma, diverting metabolites toward biosynthesis. As such, these data suggest that the metabolic aberrations induced by EF are important contributors to the oncogenic biology of these tumors. Implications: This previously unexplored role of EWS/FLI1–driven metabolic changes expands the understanding of Ewing sarcoma biology, and has potential to significantly inform development of therapeutic strategies. Mol Cancer Res; 15(11); 1517–30. ©2017 AACR.

[1]  M. Kauer,et al.  EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells , 2017, OncoTarget.

[2]  Anushya Muruganujan,et al.  PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements , 2016, Nucleic Acids Res..

[3]  Karen H. Vousden,et al.  Serine and one-carbon metabolism in cancer , 2016, Nature Reviews Cancer.

[4]  Jianguo Xia,et al.  Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis , 2016, Current protocols in bioinformatics.

[5]  D. Sabatini,et al.  A PHGDH inhibitor reveals coordination of serine synthesis and 1-carbon unit fate , 2016, Nature chemical biology.

[6]  C. Thompson,et al.  The Emerging Hallmarks of Cancer Metabolism. , 2016, Cell metabolism.

[7]  R. Deberardinis,et al.  NRF2 regulates serine biosynthesis in non-small cell lung cancer , 2015, Nature Genetics.

[8]  T. Gorr,et al.  IL6 secreted by Ewing sarcoma tumor microenvironment confers anti-apoptotic and cell-disseminating paracrine responses in Ewing sarcoma cells , 2015, BMC Cancer.

[9]  Kiyong Na,et al.  IDH Mutation Analysis in Ewing Sarcoma Family Tumors , 2015, Journal of pathology and translational medicine.

[10]  K. Janes.  An analysis of critical factors for quantitative immunoblotting , 2015, Science Signaling.

[11]  Libing Song,et al.  cMyc-mediated activation of serine biosynthesis pathway is critical for cancer progression under nutrient deprivation conditions , 2015, Cell Research.

[12]  M. V. Vander Heiden,et al.  Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d-2-Hydroxyglutarate , 2014, ACS chemical biology.

[13]  Shawn M. Gillespie,et al.  EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. , 2014, Cancer cell.

[14]  Zhandong Liu,et al.  Serine catabolism regulates mitochondrial redox control during hypoxia. , 2014, Cancer discovery.

[15]  Jun S. Wei,et al.  The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation , 2014, PLoS genetics.

[16]  M. Beckerle,et al.  Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth , 2014, Clinical Cancer Research.

[17]  J. Rabinowitz,et al.  Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate and promotes histone methylation , 2014, Cancer & Metabolism.

[18]  A. Castro,et al.  Partial inhibition of Cdk1 in G2 phase overrides the SAC and decouples mitotic events , 2014, Cell cycle.

[19]  Allen R. Chen,et al.  WT1 regulates angiogenesis in Ewing Sarcoma , 2014, Oncotarget.

[20]  A. Martínez-Torteya,et al.  SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival Analysis , 2013, PloS one.

[21]  P. Meltzer,et al.  Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer , 2013, Genome research.

[22]  J. Locasale.  Serine, glycine and one-carbon units: cancer metabolism in full circle , 2013, Nature Reviews Cancer.

[23]  Christine E. Cutucache,et al.  Amyloid precursor-like protein 2 suppresses irradiation-induced apoptosis in Ewing sarcoma cells and is elevated in immune-evasive Ewing sarcoma cells , 2013, Cancer biology & therapy.

[24]  R. Bell,et al.  EWS and RE1-Silencing Transcription Factor Inhibit Neuronal Phenotype Development and Oncogenic Transformation in Ewing Sarcoma. , 2013, Genes & cancer.

[25]  C. Wright,et al.  Ongoing Notch signaling maintains phenotypic fidelity in the adult exocrine pancreas. , 2012, Developmental biology.

[26]  M. Beckerle,et al.  The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma. , 2012, Genes & cancer.

[27]  M. Keefe,et al.  β-catenin is selectively required for the expansion and regeneration of mature pancreatic acinar cells in mice , 2012, Disease Models & Mechanisms.

[28]  S. Knuutila,et al.  High Expression of Complement Component 5 (C5) at Tumor Site Associates with Superior Survival in Ewing's Sarcoma Family of Tumour Patients , 2011, ISRN oncology.

[29]  Gregory Stephanopoulos,et al.  Amplification of phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis , 2012, BMC Proceedings.

[30]  Jianguo Xia,et al.  Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst , 2011, Nature Protocols.

[31]  Stephen P. Ethier,et al.  Oncogene Activation Induces Metabolic Transformation Resulting in Insulin-Independence in Human Breast Cancer Cells , 2011, PloS one.

[32]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[33]  이연수.  Functional genomics reveal that the serine synthesis pathway is essential in breast cancer , 2011 .

[34]  H. Drexler,et al.  Detecting mycoplasma contamination in cell cultures by polymerase chain reaction. , 2011, Methods in molecular biology.

[35]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[36]  A. Üren,et al.  GLI1 Is a Direct Transcriptional Target of EWS-FLI1 Oncoprotein* , 2009, Journal of Biological Chemistry.

[37]  J. L. Goodman,et al.  Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia , 2008, Proceedings of the National Academy of Sciences.

[38]  J. Ross,et al.  Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975‐1999 , 2008, Cancer.

[39]  Aaron R Cooper,et al.  BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression. , 2008, Cancer research.

[40]  Stephen C. Haroldsen,et al.  Microsatellites as EWS/FLI response elements in Ewing's sarcoma , 2008, Proceedings of the National Academy of Sciences.

[41]  Natalie K. Wolf,et al.  IGF1 Is a Common Target Gene of Ewing's Sarcoma Fusion Proteins in Mesenchymal Progenitor Cells , 2008, PloS one.

[42]  J. Y. Lee,et al.  Positive regulation of promoter activity of human 3-phosphoglycerate dehydrogenase (PHGDH) gene is mediated by transcription factors Sp1 and NF-Y. , 2008, Gene.

[43]  K. Laschinger,et al.  Ewing's sarcoma family of tumors: an overview from diagnosis to survivorship. , 2008, Clinical journal of oncology nursing.

[44]  S. Lessnick,et al.  A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature , 2008, Cell cycle.

[45]  S. Lessnick,et al.  Expression of EWS-ETS Fusions in NIH3T3 Cells Reveals Significant Differences to Ewing’s Sarcoma , 2006, Cell cycle.

[46]  S. Lessnick,et al.  NR0B1 Is Required for the Oncogenic Phenotype Mediated by EWS/FLI in Ewing's Sarcoma , 2006, Molecular Cancer Research.

[47]  T. Golub,et al.  Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. , 2006, Cancer cell.

[48]  A. Trumpp,et al.  Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. , 2005, Cancer research.

[49]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Michael L. Blackburn,et al.  Targeting of EWS/FLI‐1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro , 2004, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[51]  Fran Lewitter,et al.  siRNA Selection Server: an automated siRNA oligonucleotide prediction server , 2004, Nucleic Acids Res..

[52]  Anton Buzdin,et al.  Improving specificity of DNA hybridization-based methods. , 2004, Nucleic acids research.

[53]  T. Golub,et al.  Supplemental Information for , 2002 .

[54]  C. Denny,et al.  The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1 , 1993, Molecular and cellular biology.